Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Table S1. Internal validation for overall survival by 1000 bootstrap resampling

Variables	Observed HR	SE	Bootstrap 1000 95% CI	*p*
Line of therapy [1]	Reference			
2	1.528	0.315	0.804-2.737	0.150
3 or more	1.640	0.320	0.865-3.114	0.109
HER2 positive [negative]	Reference			
Positive	0.465	0.398	0.209-0.996	**0.030**
NA	0.600	3.715	0.000-2.465	0.424
SII $\geq$ 823×10^9/L [<823× 10^9/L]	2.488	0.254	1.570-4.293	**0.001**
CT-determined sarcopenia	1.410	0.274	0.848-2.430	0.174
SFA high [low]	0.422	0.311	0.216-0.725	**0.004**

Abbreviations: HR, hazard ratio; SE, standard error; CI, confidence interval;

Figure S1. Kaplan–Meier survival curves with log-rank tests were conducted according to sex, age, SII and PD-L1 expression between low and high SFA groups.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Figure S2. Kaplan–Meier survival curves with log-rank tests were conducted according to sex,

**age, SII and PD-L1 expression between low and high SII groups.**

Figure S3. Clinical characteristics and body composition parameters of high and low SFA

groups.